Description
| Source |
Applications |
Cross-reactivity |
Antibody Type |
M.W. of Caspase-9 |
| Mouse |
WB |
H, M, R |
IgG1 |
47/37/35 or 51/39/37kD |
WB, Western blot.
H, human; M, mouse; R, rat.
47/37/35kD for human Caspase-9, 51/39/37kD for mouse or rat Caspase-9.
This antibody is a Caspase-9 mouse monoclonal antibody prepared by immunizing mouse with the recombinant Caspase-9. The clone number is C9 (Clone C9). The antibody type is Mouse IgG1.
This antibody recognizes full-length Caspase-9 (sometimes called Procaspase-9 or precursor) as well as Caspase-9 fragments generated by cleavage of procaspase-9. No cross-reactivity with other Caspase family members has been detected. Human Caspase-9 (47kD) produces 37kD and 35kD fragments after cleavage, and mouse or rat Caspase-9 (51kD) generates 39kD and 37kD fragments after cleavage.
Caspase (Cysteine-requiring Aspartate Protease) is a family of proteases that play an important role in apoptosis. Caspase-9, also known as ICE-LAP6 or Mch6, is a caspase that is more upstream in apoptosis signaling. After the release of cytochrome c from mitochondria, caspase-9 can form a complex with cytochrome c and Apaf1 and be activated at the same time. Activated caspase-9 can activate caspase-3, the most critical enzyme in apoptosis, to promote the subsequent apoptotic signaling. The activation of caspase-9 can be regulated by phosphorylation.
A Primary Antibody Dilution Buffer is provided with this product and can be used for primary antibody dilution in Western blot or other applications.
The recommended dilution factor for using this product in Western blot is 1:1000, which can be adjusted according to the actual level of antigen.
When using for routine Western blot, this product is sufficient for at least 10 blots.
Packing List
| Item |
Component |
Quantity |
| AC062-1 |
Caspase-9 Mouse Monoclonal Antibody |
10μl |
| AC062-2 |
Primary Antibody Dilution Buffer for Western Blot |
10ml |
| Manual |
– |
1 copy |
Storage Conditions：
Store the Antibody at -20℃ and Primary Antibody Dilution Buffer at 4℃ for up to one year. The Primary Antibody Dilution Buffer can be stored at -20℃ for lone-term storage, but freeze-thaw may result in slight turbidity and a small amount of insoluble substance.
Precautions：
For Western blot analysis with this antibody, membranes should be incubated overnight in the diluted antibody at 4℃ with shaking slowly. Shorter incubation will be less effective.
This product can be recovered for multiple reuses (at least 10 times) in Western blot (WB). Store the unused or recovered diluted antibodies at 4℃.
The recovered antibodies can be reused in the same way as freshly diluted antibodies. If slight turbidity appears, centrifuge the antibody at 10,000×g for 1-3 minutes and use the supernatant for subsequent assays. But it should be discarded when there is significant flocculation or any microbial growth.
This product is for R&D only. Not for drug, household, or other uses.
For your safety and health, please wear a lab coat and disposable gloves during the operation.
Instruction
Instructions for Use：
1. Western blot
a. Dilute an appropriate amount of the antibody with the provided Primary Antibody Dilution Buffer to an appropriate concentration as required.
b. Transfer the blocked membrane into the diluted primary antibody and incubate at room temperature for 2 hours or overnight at 4℃ with gently shaking. The membrane should be covered completely by the diluted antibody.
c. Recover the diluted primary antibody and store at 4℃ for later use.
d. Proceed to next step in Western blot. For detailed procedures of Western blot, please refer to http://www.beyotime.com/support/western.htm.
References
Related papers：
1. Pei J, Deng J, Ye Z, Wang J, Gou H, Liu W, Zhao M, Liao M, Yi L, Chen J .
.
Autophagy. 2016 Oct 2;12(10):1738-58. (IF 9.77)
2. Wenhui Li, Zilin Zhang, Liangliang Zhang, Qingfeng Zhou, Yuwan Li, Lin Yi, Hongxing Ding, Mingqiu Zhao, Jinding Chen, Shuangqi Fan
.
Virulence. 2022 Dec;13(1):1720-1740. doi: 10.1080/21505594.2022.2127241. (IF 5.542)
3. Qing-Zhou Chen, Xin Wang, Fan Luo, Ning Li, Ni Zhu, Shuang Lu, Yu-Xing Zan, Chao-Jie Zhong, Mei-Rong Wang, Hai-Tao Hu, Yong-Zhen Zhang, Hai-Rong Xiong, Wei Hou
.
Front Immunol. 2020 Jun 19;11:1072. doi: 10.3389/fimmu.2020.01072. (IF 5.085)
4. Gao Z, Kang X, Hu J, Ju Y, Xu C.
.
Cytotechnology. 2012 Aug;64(4):421-8. (IF 1.777)
5. Kang X, Hu J, Gao Z, Ju Y, Xu C.
.
MEDCHEMCOMM. 2012 Aug;10:1245-9. (IF 2.807)
6. Zhang C, Zhao J, Deng H.
.
Mol Cell Biochem. 2013 Jul;379(1-2):201-11. (IF 2.795)
7. Zhang Y, Duan W, Owusu L, Wu D, Xin Y.
.
Int J Mol Med. 2015 Jan;35(1):117-24. (IF 3.098)
8. Wang YH, Zhao WJ, Zheng WJ, Mao L, Lian HZ, Hu X, Hua ZC .
.
Biol Trace Elem Res. 2016 Mar;170(1):75-83. (IF 2.639)
9. Jing HX, Duan de J, Zhou H, Hu QM, Lei TC .
.
Mol Med Rep. 2016 Jul;14(1):195-201. (IF 2.1)
10. Yu XB, Chen XH, Ling F, Hao K, Wang GX, Zhu B .
.
ANTIVIR RES. 2016 Jul;131:156-65. (IF 4.101)
11. Han YY, Tang JJ, Gao RF, Guo X, Lei M, Gao JM .
.
Toxicol In Vitro. 2016 Sep;35:112-20. (IF 2.959)
12. Peng X, Gan J, Wang Q, Shi Z, Xia X .
.
Toxicology. 2016 Nov 30;372:1-11. (IF 4.099)
13. Zhong Y, Jin C, Gan J, Wang X, Shi Z, Xia X, Peng X.
.
Toxicon. 2017 Oct;137:106-113. (IF 2.201)
14. Kang J, Jia Z, Ping Y, Liu Z, Yan X, Xing G, Yan W
.
Arch Biochem Biophys. 2018 Jul 1;649:53-59. (IF 3.391)
15. Zhong Y, Jin C, Wang X, Li X, Han J, Xue W, Wu P, Peng X, Xia X
.
CHEM-BIOL INTERACT. 2018 Dec 25;296:9-17. (IF 3.723)
16. Ding L, Gu H, Lan Z, Lei Q, Wang W, Ruan J, Yu M, Lin J, Cui Q
.
Oncol Rep. 2019 Jan 41(1):559-569. (IF 3.417)
17. Biqian Fu, Shengyan Xi, Yanhui Wang, Xiangyang Zhai, Yanan Wang, Yuewen Gong, Yangxinzi Xu, Jiaqi Yang, Yingkun Qiu, Jing Wang, Dawei Lu, Shuqiong Huang
.
Front Pharmacol. 2019 Jan 8;9:1539. doi: 10.3389/fphar.2018.01539. (IF 4.225)
18. Xu J, Zhang G, Tong Y, Yuan J, Li Y, Song G
.
Int J Mol Med. 2019 Feb 43(2):967-979. (IF 3.098)
19. Ma Y, Wang Y, Song B
.
Breast Cancer. 2019 Mar 26(2):190-197. (IF 2.695)
20. Yanchun M, Yi W, Lu W, Yu Q, Jian Y, Pengzhou K, Ting Y, Hongyi L, Fang W, Xiaolong C, Yongping C
.
Eur J Pharmacol. 2019 May 15 851:43-51. (IF 3.263)
21. Xu Bai, Yu Wang, Bo Hu, Qi Cao, Maochen Xing, Shuliang Song, Aiguo Ji
.
Mar Drugs. 2020 Apr 20;18(4):220. doi: 10.3390/md18040220. (IF 4.073)
22. Haifeng Jin, Yu Jiao, Linna Guo, Yong Ma, Rongjie Zhao, Xuemei Li, Lei Shen, Zhongguang Zhou, Sang Chan Kim, Jicheng Liu
.
Int J Mol Med. 2021 Feb;47(2):595-606. doi: 10.3892/ijmm.2020.4813. (IF 3.098)
23. Jingjing Zong, Hao Peng, Xin Qing, Zhe Fan, Wenjing Xu, Xuanlong Du, Ruihua Shi, Yewei Zhang
.
ACS Omega. 2021 Apr 30;6(18):12331-12342. doi: 10.1021/acsomega.1c01346. (IF 2.87)
24. Bo Yan, Shao-Ju Min, Bin Xu, Cheng Zhang, Jun Pei, Wei Zhang, Guang-Heng Luo
.
Transl Androl Urol. 2021 May;10(5):2051-2066. doi: 10.21037/tau-21-280. (IF 2.445)
25. Meijuan Meng, Lairong Wang, Yan Wang, Nana Ma, Wan Xie, Guangjun Chang, Xiangzhen Shen
.
J Dairy Sci. 2022 Apr;105(4):3416-3429. doi: 10.3168/jds.2021-21187. (IF 3.333)
26. Yuanyuan Zheng, Longhao Wang, Xiaoyu Niu, Yongjun Guo, Jiuzhou Zhao, Lifeng Li, Jie Zhao
.
BMC Cancer. 2023 Jan 7;23(1):28. doi: 10.1186/s12885-023-10506-0.
27. Wei Hua, Shuainan Ma, Yuxin Pang, Qi Liu, Yueying Wang, Zhiyi Liu, Nan Zhao, Naixin Ren, Sinan Jin, Benshuai Wang, Yuejia Song, Jiping Qi
.
Mol Neurobiol. 2023 Dec;60(12):7060-7079. doi: 10.1007/s12035-023-03484-8.
28. Nina Wang, Lei Zhang, Junjie Yu, Kaili Chang, Minghui Fan, Zi Liu, Liang Ma, Jianguo Cao, Guozheng Huang
.
Chem Biodivers. 2024 Jun;21(6):e202301248. doi: 10.1002/cbdv.202301248.
